ReviewThe Journal of international medical research2019
Pathogenesis of and major animal models used for nonalcoholic fatty liver disease.
Review in The Journal of international medical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Comparison and Characteristics of MASLD Mouse Models.Biomedicines · 2026Review
- Transcriptomic analysis identifies FABP5 as a candidate regulator of lipid accumulation in metabolic dysfunction-associated fatty liver disease.Frontiers in endocrinology · 2026Article
- Review on the Relationship Between TyG Index and CVD Incidence in Patients With T2DM With NAFLD.International journal of endocrinology · 2026Review
- Obesity-Induced MASLD Is Reversed by Capsaicin via Hepatic TRPV1 Activation.Current issues in molecular biology · 2025Article
- Multi-omics analysis of a fatty liver model using human hepatocyte chimeric mice.Scientific reports · 2024Article
- Phenotypic and metabolomic characteristics of mouse models of metabolic associated steatohepatitis.Biomarker research · 2024Article
- The interaction of Schistosoma mansoni infection with diabetes mellitus and obesity in mice.Scientific reports · 2023Article
- Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease.Seminars in liver disease · 2022Review
- Association Between Triglyceride-Glucose Index and Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Article
- NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer.Frontiers in pharmacology · 2022Article
- [Research progress on non-alcoholic fatty liver disease animal models].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021Article
- Beneficial Effects of Betaine: A Comprehensive Review.Biology · 2021Review
- Article
- NAFLD Preclinical Models: More than a Handful, Less of a Concern?Biomedicines · 2020Review
- The Effect of Rice Bran Extract on Arterial Blood Pressure, Hepatic Steatosis, and Inflammation in Mice Fed with a High-Fat Diet.Journal of nutrition and metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) and its pathologically more severe form, nonalcoholic steatohepatitis (NASH), have become prevalent worldwide and carry an increased risk of developing hepatocellular carcinoma and other metabolic diseases. Diverse animal models have been proposed to replicate particular characteristics of NAFLD and NASH and have provided significant clues to the critical molecular targets of NASH treatment. In this review, we summarize the histopathology, pathogenesis, and molecular basis of NAFLD progression and discuss the benchmark animal models of NAFLD/NASH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.